- SMA results from a homozygous deletion of SMN1 on chromosome 5q13; however, variation in phenotype is usually explainable by the number of SMN2 genes an affected individual possesses.

- Historically prognosis for type I has been extremely poor with most [atients dying before their second birthday; however, novel therapies such as onasemnogene abeparvovec and nusinersen are recently licensed medications that are showing promise at prolonging life and reducing morbidity.